HOME >> MEDICINE >> NEWS
JCI table of contents -- May 17, 2007

EDITOR'S PICK

Role of TRPM8 in the development of prostate cancer

Recent studies have indicated that the protein known as TRPM8 plays an important role in prostate cancer: high levels of TRPM8 have been found in prostate carcinoma compared to normal prostate epithelial cells, and TRPM8 has been suggested as a specific marker and therapeutic target in prostate cancer. However, the regulation of and changes in TRPM8 during prostate cancer progression have remained unclear.

In normal prostate epithelium, cells coexist in many stages of development/differentiation progressing from stem cells to mature luminal cells. Disrupted or dysregulated differentiation and proliferation are major causes of cancer. In a study appearing online on May 17 in advance of publication in the June print issue of the Journal of Clinical Investigation, Natalia Prevarskaya from Universit des Sciences et Technologies de Lille, France, show that only mature, differentiated human prostate primary epithelial luminal cells express functional plasma membrane TRPM8 (PM-TRPM8) and that prostate cancer cells possessed higher PM-TRPM8 levels than normal cells. However, endoplasmic reticulum TRPM8 (ER-TRPM8) retained its function as a calcium release channel, independent of the differentiation state of the cell, and may be an important factor in controlling the growth of prostate cancer cells. The authors hypothesize that the constant activity of ER-TRPM8 may be the result of the expression of a truncated form of TRPM8. The authors suggest that specific inhibition of ER-TRPM8 or PM-TRPM8 may prove to be of therapeutic use in the treatment of prostate cancer, depending on the stage of the tumor.

TITLE: Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function

AUTHOR CONTACT:

Natalia Prevarskaya

Universit des Sciences et Technologies d
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
17-May-2007


Page: 1 2 3 4 5 6 7

Related medicine news :

1. International symposium on fruit, vegetables headed for Houston
2. Stevens Roundtable: Health, Technology & Society, July 11
3. FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma
4. Once-fatal metabolic disorders treatable, says Stanford/Packard researcher
5. Clinical review -- A psychological approach to the management of irritable bowel syndrome
6. JCI table of contents: May 10, 2007
7. New treatments needed for irritable bowel syndrome
8. JCI table of contents: May 1, 2007
9. Americans still not eating enough fruits and vegetables, according to 2 recent studies
10. Slow-release morphine reduces level of intractable cough
11. Less television and more gathering around the dinner table prevents

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/28/2017)... ... 28, 2017 , ... Guide to FDA and EU Medical Device Regulations: 2017 ... side of the Atlantic devicemakers do business, this fully updated and expanded guide keeps ... addition to the full text of the FDA’s regulations in 21 CFR Parts 800 ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... David B. Sosin, a founding ... Illinois, took over the post of 2nd Vice President for the Illinois State Bar ... installed as the ISBA’s 3rd Vice President in 2016 following a state-wide election and served ...
(Date:6/28/2017)... Columbia (PRWEB) , ... June 28, 2017 , ... ... (FSE: ZEON) is pleased to announce that a two year study conducted by ... Company's Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... consulting firm servicing communities throughout the greater Cincinnati metropolitan area, is teaming up ... temporary lodgings for families with children receiving treatment in nearby hospitals. , Ronald ...
(Date:6/27/2017)... ... 2017 , ... Harbour , a DAO (decentralized autonomous organization) that harnesses ... released their technical specifications . , 2017 has seen an explosion of token ... determining which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... Calif. , June 9, 2017 AirXpanders, ... company focused on the design, manufacture, sale and distribution ... market on the progress of its commercial roll-out in ... now available in more than one hundred (100) medical ... AeroForm offers a needle-free alternative for women ...
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ... Joseph R. Goodwin , U.S. District Court Judge ... , entered a case management order in MDL ... Liability Litigation (the "MDL") that includes a provision requiring ... disclosures on specific causation within one hundred twenty (120) ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
Breaking Medicine Technology:
Cached News: